Turbine

Founded in 2015 and based in Budapest, Turbine has developed an AI-driven simulation platform designed to virtualize biological experiments. The company's core offering, the Virtual Lab, enables partners to simulate millions of experiments daily to inform decisions across the drug discovery and development pipeline, from target identification to clinical positioning. Turbine operates as a private, platform-technology company, generating revenue through partnerships and collaborations with pharmaceutical firms, as evidenced by its work with Ono Pharmaceutical and backing from investors like MSD's Global Health Innovation Fund.

The Simulated Cell / Virtual Lab (vLab): An AI-powered, mechanistic simulation platform that models intracellular signaling networks to virtually run biological experiments. It includes self-serve (vLab Core), custom integration (vLab Custom), and collaborative disease modeling (vLab Collaborate) offerings, supported by a wet lab-in-the-loop validation cycle.

Turbine competes in the broad AI-for-drug-discovery market against companies like Recursion, Exscientia, and Insilico Medicine. Its primary differentiation is a focus on mechanistic simulation of cell signaling, rather than solely on image analysis, generative chemistry, or clinical trial optimization. It also faces competition from large tech companies (e.g., Google's Isomorphic Labs) and internal efforts at major pharma.